Hims & Hers Health Captivates Investors: Key Insights Revealed

Key Factors Influencing Hims & Hers Health's Stock Performance

Hims & Hers Health, Inc. (HIMS) has recently gained attention as one of the most searched stocks on various platforms. This increased interest may prompt investors to evaluate several factors that could impact the company’s stock performance in the coming months.

Over the past month, shares of Hims & Hers Health have experienced a decline of -18.1%, while the Zacks S&P 500 composite saw an increase of +5.4%. Additionally, the Zacks Medical Info Systems industry, which includes Hims & Hers Health, has also seen a drop of 12.8% during this period. These figures raise the question: where is the stock headed in the near future?

While media reports or rumors about significant changes in a company’s business prospects can cause immediate price fluctuations, long-term investment decisions are often based on fundamental factors. One of the most important indicators is the change in earnings estimates.

Earnings Estimate Revisions

At Zacks, the focus is on analyzing how sell-side analysts adjust their earnings projections in response to the latest business trends. The belief is that the present value of a company’s future earnings stream determines its fair stock value. When earnings estimates rise, the fair value of the stock typically increases as well. If a stock’s fair value exceeds its current market price, it often attracts buyers, leading to an upward movement in the stock price.

For the current quarter, Hims & Hers Health is expected to report earnings of $0.17 per share, marking a +183.3% increase compared to the same period last year. The Zacks Consensus Estimate for this quarter has remained unchanged over the last 30 days.

Looking ahead, the consensus earnings estimate for the current fiscal year stands at $0.75, reflecting a +177.8% growth from the previous year. This estimate has slightly increased by +0.3% over the last 30 days. For the next fiscal year, the consensus estimate is $1.03, indicating a +37.3% increase from what the company is expected to report a year ago. The estimate has seen a small change of +0.2% over the past month.

The Zacks Rank, a proprietary stock rating tool, provides insight into a stock’s potential price direction by leveraging earnings estimate revisions. Due to the recent changes in consensus estimates and other related factors, Hims & Hers Health has been assigned a Zacks Rank of #1, which indicates a Strong Buy recommendation.

Projected Revenue Growth

Revenue growth is another critical factor in assessing a company’s financial health. While earnings growth is essential, it is nearly impossible for a company to sustain earnings growth without corresponding revenue growth.

For the current quarter, Hims & Hers Health is expected to generate $551.84 million in sales, representing a +74.8% increase from the same period last year. The estimates for the current and next fiscal years are $2.35 billion and $2.86 billion, respectively, showing growth of +58.9% and +21.8%.

Last Reported Results and Surprise History

In its last reported quarter, Hims & Hers Health generated revenues of $586.01 million, a +110.7% increase compared to the same period last year. The EPS for the quarter was $0.20, up from $0.05 a year ago.

Compared to the Zacks Consensus Estimate of $538.09 million, the reported revenues represented a surprise of +8.9%. The EPS surprise was even more significant at +66.67%.

Over the past four quarters, Hims & Hers Health has exceeded consensus EPS estimates twice and consistently surpassed revenue estimates during this time.

Valuation Considerations

Valuation plays a crucial role in making informed investment decisions. It helps determine whether a stock’s current price reflects the intrinsic value of the underlying business and its growth potential.

Comparing a company’s valuation multiples—such as the price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF)—to its historical values can indicate whether the stock is fairly valued, overvalued, or undervalued. Comparing these metrics with those of its peers also provides insight into the reasonableness of the stock price.

The Zacks Value Style Score, part of the Zacks Style Scores system, evaluates both traditional and unconventional valuation metrics to grade stocks from A to F. Hims & Hers Health has received a D rating, suggesting that it is trading at a premium relative to its peers.

Bottom Line

The information discussed here offers valuable insights into the potential performance of Hims & Hers Health. While market buzz may influence short-term movements, the company’s Zacks Rank #1 suggests it may outperform the broader market in the near term. Investors should consider all these factors before making any decisions.